Welcome to our dedicated page for Biodexa Pharmaceuticals plc news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals plc stock.
Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company whose news flow centers on the clinical and regulatory progress of its lead programs eRapa, tolimidone and MTX110. Company announcements and SEC Form 6-K filings describe ongoing activity in familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes and rare or orphan brain cancers.
Investors following BDRX news can expect regular updates on the Serenta Phase 3 trial of eRapa in FAP, including milestones such as enrollment of the first patients, activation of new clinical sites in the United States and Europe, and approval of a Clinical Trial Application by the European Medicines Agency. Releases also provide context on the FAP disease burden and the lack of approved non-surgical treatment options, which frame the rationale for eRapa’s development.
Biodexa’s news stream also covers pipeline developments beyond FAP. The company reports progress in a Phase 2 study of eRapa in NMIBC, a Phase 2a investigator-initiated trial of tolimidone in type 1 diabetes, and early-stage studies of MTX110 in aggressive brain cancers. Operational updates, such as orphan drug designations, Fast Track designation, and collaborations with organizations like Emtora Biosciences, LumaBridge and Precision for Medicine, feature prominently.
In addition, BDRX news includes corporate and financing events such as equity line agreements, warrant transactions, ADR ratio changes and public offerings of ADS Units and pre-funded units, as detailed in Form 6-K filings. Governance and leadership changes, including board appointments and executive role updates, are also disclosed through press releases. For readers tracking BDRX, this news page offers a consolidated view of clinical milestones, regulatory steps and capital markets activity related to Biodexa’s development programs.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced a partnership with Syngene to manufacture GMP clinical trial supplies of MTX240, covering both the active pharmaceutical ingredient and dosage form.
According to the company, Syngene previously manufactured tolimidone on time and on budget and, following Biodexa's MTX240 license from Otsuka in early February, designed a GMP program within a few weeks.
Biodexa (Nasdaq: BDRX) and Tanner Pharma Group launched a global Early Access / Named Patient Program for eRapa to treat Familial Adenomatous Polyposis (FAP) on March 31, 2026. The program enables clinicians to prescribe investigational oral rapamycin capsules outside clinical trials where local regulations permit.
The initiative aims to expand access, provide compliant, controlled supply in countries where eRapa is not available, and collect Real World Data (RWD) to improve understanding of FAP and patient experience. Access depends on patient eligibility, local laws, and funding availability.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced audited preliminary results for the year ended 31 December 2025. The company is a clinical-stage biopharmaceutical focused on treatments and prevention for gastrointestinal cancers. Contact details provided include CEO Stephen Stamp and CFO Fiona Sharp.
The announcement confirms the availability of audited preliminary results and directs stakeholders to Biodexa for further information.
Biodexa (Nasdaq: BDRX) has launched a global Early Access Program for its investigational medicine eRapa to treat Familial Adenomatous Polyposis (FAP) patients via a strategic partnership with Tanner Pharma Group.
The program enables clinicians worldwide to prescribe eRapa outside clinical trials, subject to local laws and funding, and Biodexa will collect Real World Data to better understand FAP patient experiences.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an ADR ratio change from 1 ADR = 100,000 ordinary shares to 1 ADR = 500,000 ordinary shares, effective on or about April 6, 2026. ADR holders must surrender five old ADRs for one new ADR (New CUSIP: 59564R872).
The change will operate as a one-for-five reverse ADR split for ADRs only; ordinary shares are not affected. The depositary, JP Morgan Chase Bank, N.A., will manage exchanges and sell any aggregate fractional interests, distributing net proceeds. The Company said the change aims to comply with Nasdaq's $1.00 minimum bid requirement but gave no assurance it will achieve that outcome.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an initial financial grant supporting the launch of Life's a Polyp Foundation, the first U.S. patient advocacy group focused exclusively on Familial Adenomatous Polyposis (FAP).
Biodexa highlighted its lead program eRapa, an encapsulated rapamycin in the registrational Phase 3 Serenta trial with >20% enrollment and FDA Fast Track designation, and said the grant aims to boost patient resources, community support, and awareness for FAP patients and families.
Biodexa (NASDAQ:BDRX) licensed MTX240, a Phase 1–ready molecular glue for gastrointestinal stromal tumors (GIST), from Otsuka on February 19, 2026.
MTX240 showed dose-dependent preclinical efficacy in TKI-resistant and non-resistant GIST models, is eligible for US/EU Orphan Drug exclusivity, has composition‑of‑matter patents through 2037, and a Phase 1b/2a trial is planned by year-end.
Biodexa (Nasdaq: BDRX) closed an exclusive license with Otsuka for OPB-171775, a Phase 1–ready molecular glue intended for treatment of gastrointestinal stromal tumours (GIST). Biodexa will develop the asset as MTX240, citing activity in TKI‑resistant PDX models and potential use in additional indications. The program aligns with Biodexa's GI/oncology pipeline alongside its Phase 3 eRapa program in Familial Adenomatous Polyposis.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced on January 5, 2026 the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary and her election to the Board of Directors, effective immediately.
Ms Sharp joined Biodexa as Group Financial Controller in December 2019 and has assumed many CFO responsibilities during her tenure. Her prior roles include Assistant Director of Finance at Hywel Dda University Health Board (over 10,000 staff; budget ~£800 million) and senior finance roles at Chime Communications Group (revenues ~£570 million) from 1999 until early 2018. Stephen Stamp will relinquish his CFO and Company Secretary roles but will remain as Chief Executive Officer.
Biodexa Pharmaceuticals (Nasdaq: BDRX) priced a best efforts public offering expected to raise aggregate gross proceeds of approximately $10.0 million before fees and expenses. The offering consists of (i) 157,000 ADS Units (one ADS representing 100,000 ordinary shares plus two Series L warrants) at a combined price of $3.28 per ADS Unit, and (ii) 2,891,781 pre-funded units at $3.2799 each. Each Series L Warrant is immediately exercisable at $3.28 and expires five years after issuance. The company intends to use net proceeds for development programs, working capital and general corporate purposes. The offering is expected to close on December 19, 2025, subject to customary closing conditions; Maxim Group is sole placement agent and the SEC declared the registration statement effective on December 17, 2025.